AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7949749 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral calcium dose of 2 g (group 2, n = 17)
Number of subjects: 74
Study 7949749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclic etidronate therapy (group 3, n = 19)
Number of subjects: 74
Study 7949749 — intervention group
Group type: EXPERIMENTAL
Intervention: ADFR treatment with triiodothyronine and etidronate (group 4, n = 18)
Number of subjects: 74
Study 3358644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 5.7 mg)
Number of subjects: 525
Study 3358644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 525
Study 3358644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean daily dose 7.5 capsules)
Number of subjects: 525
Study 30390894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support (126 kJ/kg and 1.5-2.0 g protein/kg) during hospitalization
Number of subjects: 119
Study 30390894 — intervention group
Group type: COMPARATOR
Intervention: Routine feeding (control group)
Number of subjects: 119
Study 30390894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 119
Study 28166812 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU-assisted liver resection (HIFU-AR)
Number of subjects: 42
Study 28166812 — intervention group
Group type: COMPARATOR
Intervention: Standard crushing technique (Control)
Number of subjects: 42
Study 28166812 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU-AR
Number of subjects: 42
Study 26414380 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 91
Study 26414380 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 91
Study 26414380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 91
Study 22889336 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST)
Number of subjects: 158
Study 22889336 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHKO
Number of subjects: 158
Study 22889336 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 158
Study 21124326 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus a calcium channel blocker (CCB)
Number of subjects: 65
Study 21124326 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan plus a thiazide diuretic
Number of subjects: 65
Study 19145003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 8600
Study 19145003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8600
Study 17925548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and taxane regimens
Number of subjects: 914
Study 17925548 — intervention group
Group type: COMPARATOR
Intervention: Previously reported genotype associations
Number of subjects: 914
Study 15310999 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (luteinizing hormone‐releasing hormone agonist and 1 month of antiandrogen treatment or surgical castration)
Number of subjects: 302
Study 15310999 — intervention group
Group type: COMPARATOR
Intervention: Delayed endocrine treatment
Number of subjects: 302
Study 11510901 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave application (ESWA)
Number of subjects: 42
Study 9574876 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Test
Number of subjects: 28
Study 9574876 — intervention group
Group type: EXPERIMENTAL
Intervention: ALK lancet
Number of subjects: 28
Study 8534760 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol amphotericin B inhalations (10 mg twice daily)
Number of subjects: 115
Study 8534760 — intervention group
Group type: COMPARATOR
Intervention: No aerosol amphotericin B prophylaxis
Number of subjects: 115
Study 2143046 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg two or three times daily for 3 months
Number of subjects: 31
Study 2143046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 318609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 100
Study 318609 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole
Number of subjects: 100
Study 31232992 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Number of subjects: 14
Study 31232992 — intervention group
Group type: COMPARATOR
Intervention: Intraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Number of subjects: 14
Study 31232992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (Extraoral and Intraoral)
Number of subjects: 14
Study 28363363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.25 mg/kg/dose every 6 hours for 48 hours
Number of subjects: 60
Study 28363363 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 hours for 48 hours
Number of subjects: 60
Study 28363363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) for simple effusion
Number of subjects: 60
Study 28363363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for simple effusion
Number of subjects: 60
Study 28363363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) for complicated effusion
Number of subjects: 60
Study 28363363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for complicated effusion
Number of subjects: 60
Study 26198855 — intervention group
Group type: EXPERIMENTAL
Intervention: CARe methodology training from a specialized institute
Number of subjects: 0
Study 26198855 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23972540 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT) and Body Talk Cortices (BTC) for 6 months, with weekly HT sessions and daily BTC technique.
Number of subjects: 22
Study 23972540 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional interventions.
Number of subjects: 22
Study 21912341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual-elastic compression stockings (GCSs)
Number of subjects: 16
Study 21912341 — intervention group
Group type: COMPARATOR
Intervention: Control (no GCSs)
Number of subjects: 16
Study 18326222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizhne-Ivkinskaya 2K mineral water for 21 days
Number of subjects: 134
Study 18326222 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 134
Study 16359741 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5mg/day
Number of subjects: 24
Study 16359741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15011964 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 27
Study 15011964 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 27
Study 11117090 — intervention group
Group type: COMPARATOR
Intervention: pre‐eclampsia/eclampsia syndrome
Number of subjects: 66
Study 11117090 — intervention group
Group type: COMPARATOR
Intervention: eclamptic patients
Number of subjects: 66
Study 11117090 — intervention group
Group type: COMPARATOR
Intervention: pre‐eclamptic patients
Number of subjects: 66
Study 11117090 — intervention group
Group type: COMPARATOR
Intervention: isolated HELLP syndrome
Number of subjects: 66
Study 2187585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg orally three times a day)
Number of subjects: 295
Study 2187585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 7033008 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-phe insulin (regular and semilinte preparations)
Number of subjects: 24
Study 7033008 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-phe insulin
Number of subjects: 24
Study 7033008 — intervention group
Group type: COMPARATOR
Intervention: Unmodified insulin
Number of subjects: 24
Study 31951260 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence‐Based Amputee Rehabilitation program
Number of subjects: 20
Study 31951260 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 20
Study 30426602 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy (RARH)
Number of subjects: 121
Study 30426602 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic radical hysterectomy (LRH)
Number of subjects: 121
Study 28954583 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microTesla MF (3 minutes duration) at three frequencies (10, 14 and 18 Hz)
Number of subjects: 65
Study 28954583 — intervention group
Group type: COMPARATOR
Intervention: Sham operation
Number of subjects: 65
Study 28954583 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF-MF exposure
Number of subjects: 65
Study 27519620 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination of SA3Ag
Number of subjects: 345
Study 27519620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 27519620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose level SA3Ag
Number of subjects: 345
Study 27519620 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial vaccination of SA3Ag
Number of subjects: 345
Study 24969735 — intervention group
Group type: EXPERIMENTAL
Intervention: Weed-Check (motivational interviewing intervention)
Number of subjects: 119
Study 24969735 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study 22336473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200mg/day)
Number of subjects: 106
Study 22336473 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100mg/day)
Number of subjects: 106
Study 20511269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred work accommodations (fewer work hours, working from home, slower work pace, more autonomy in planning work tasks)
Number of subjects: 122
Study 20511269 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial problems (work-home interference, lack of acceptance of chronic disease)
Number of subjects: 122
Study 20511269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 122
Study 20511269 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing psychosocial problems
Number of subjects: 122
Study 17685844 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM gel with a diaphragm
Number of subjects: 120
Study 16015060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapies including protection and thromboaspiration devices, new atherectomy devices, and cryoplasty.
Number of subjects: 0
Study 12037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum from asthmatic patients
Number of subjects: 25
Study 12037225 — intervention group
Group type: COMPARATOR
Intervention: Induced sputum from normal control subjects
Number of subjects: 25
Study 12037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with FEV(1) % predicted
Number of subjects: 25
Study 12037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with bronchial hyperreactivity to methacholine
Number of subjects: 25
Study 12037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with eosinophilic airway inflammation (% eosinophils)
Number of subjects: 25
Study 12037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with eosinophil cationic protein
Number of subjects: 25
Study 10543269 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSV in sitting posture
Number of subjects: 12
Study 10543269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting NPSV
Number of subjects: 12
Study 10543269 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS (Visual Analogue Scale)
Number of subjects: 12
Study 10543269 — intervention group
Group type: COMPARATOR
Intervention: Changing posture
Number of subjects: 12
Study 7783062 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg qid
Number of subjects: 40
Study 7783062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2515524 — intervention group
Group type: EXPERIMENTAL
Intervention: Altretamine preparation 1
Number of subjects: 0
Study 2515524 — intervention group
Group type: EXPERIMENTAL
Intervention: Altretamine preparation 2
Number of subjects: 0
Study 2515524 — intervention group
Group type: COMPARATOR
Intervention: Altretamine preparation 3 (control)
Number of subjects: 0
Study 7253868 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-blood trial after 920 ml equivalent of whole blood
Number of subjects: 12
Study 31811339 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel dressing
Number of subjects: 24
Study 31811339 — intervention group
Group type: COMPARATOR
Intervention: Saline dressing (Control)
Number of subjects: 24
Study 28658251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 224
Study 28658251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 28658251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drug detected
Number of subjects: 224
Study 28658251 — intervention group
Group type: EXPERIMENTAL
Intervention: No oral drug detected
Number of subjects: 224
Study 26449801 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-oncology training program (16 hours)
Number of subjects: 96
Study 26449801 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 96
Study 25296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch (21 mg every 24 hours)
Number of subjects: 341
Study 22532189 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure at 6 W/kg (maxSAR10g in the head)
Number of subjects: 0
Study 22532189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure at 1.5 W/kg (maxSAR10g in the head)
Number of subjects: 0
Study 22532189 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 0
Study 22532189 — intervention group
Group type: COMPARATOR
Intervention: Control software for exposure monitoring
Number of subjects: 0
Study 22532189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure uncertainty analysis
Number of subjects: 0
Study 20433806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccination after topical application of imiquimod (250 mg)
Number of subjects: 21
Study 20433806 — intervention group
Group type: COMPARATOR
Intervention: Intradermal hepatitis B vaccination without imiquimod application (control group)
Number of subjects: 21
Study 18760149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous BCAA supplementation (n=22; 19.6g/d)
Number of subjects: 41
Study 18760149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous; n=19)
Number of subjects: 41
Study 15991648 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-CASI
Number of subjects: 1500
Study 15991648 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1500
Study 15991648 — intervention group
Group type: COMPARATOR
Intervention: Self-administered questionnaires
Number of subjects: 1500
Study 11910268 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ziprasidone
Number of subjects: 90
Study 11910268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 90
Study 11910268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10625156 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD CPR)
Number of subjects: 302
Study 10625156 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 302
Study 7725886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2.5 mg/ml
Number of subjects: 32
Study 7725886 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 32
Study 2117190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen treatment
Number of subjects: 46
Study 2117190 — intervention group
Group type: COMPARATOR
Intervention: No oxygen treatment
Number of subjects: 46
Study 6679234 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin hydrochloride (long-term therapy)
Number of subjects: 0
Study 6679234 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 6679234 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin hydrochloride (short-term therapy)
Number of subjects: 0
Study 31150095 — intervention group
Group type: EXPERIMENTAL
Intervention: LB 133 mg
Number of subjects: 155
Study 31150095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 31065885 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 556
Study 31065885 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 556
Study 31065885 — intervention group
Group type: COMPARATOR
Intervention: Market prices for SICS
Number of subjects: 556
Study 31065885 — intervention group
Group type: COMPARATOR
Intervention: Market prices for phacoemulsification
Number of subjects: 556
Study 29016711 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinks Meter
Number of subjects: 402
Study 29016711 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTooMany
Number of subjects: 402
Study 26035185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 462
Study 26035185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 462
Study 26035185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 25127173 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2951742 (150 mg) subcutaneous injection every 2 weeks for 12 weeks
Number of subjects: 218
Study 25127173 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneous injection every 2 weeks for 12 weeks
Number of subjects: 218
Study 25127173 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2951742
Number of subjects: 218
Study 25127173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 22865902 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3
Number of subjects: 305
Study 22865902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 305
Study 22865902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 22865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 305
Study 19203562 — intervention group
Group type: EXPERIMENTAL
Intervention: CET + PSE (10 mg cetirizine and 120 mg pseudoephedrine)
Number of subjects: 49
Study 19203562 — intervention group
Group type: COMPARATOR
Intervention: CET (single treatment)
Number of subjects: 49
Study 19203562 — intervention group
Group type: COMPARATOR
Intervention: PSE (single treatment)
Number of subjects: 49
Study 19203562 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 49
Study 17680909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) + pharmacotherapy
Number of subjects: 90
Study 17680909 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 90
Study 15169696 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day, with option to increase to 40 mg/day at week 4)
Number of subjects: 174
Study 15169696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 15169696 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 174
Study 11433064 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram of LD vaccine
Number of subjects: 4090
Study 11433064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4090
Study 9757887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes plus oxytocin (2 IU injected plus 0.07 IU/min infused for 60 minutes)
Number of subjects: 7
Study 9757887 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes
Number of subjects: 7
Study 8000461 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning
Number of subjects: 30
Study 8000461 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care
Number of subjects: 30
Study 8000461 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 30
Study 8000461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted turning
Number of subjects: 30
Study 8000461 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range-of-motion exercises
Number of subjects: 30
Study 8000461 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior bath
Number of subjects: 30
Study 8000461 — intervention group
Group type: COMPARATOR
Intervention: Order of interventions
Number of subjects: 30
Study 3287685 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with vincristine, prednisone, L‐asparaginase and rubidomycin (Group B)
Number of subjects: 240
Study 3287685 — intervention group
Group type: COMPARATOR
Intervention: Induction treatment with vincristine, prednisone and L‐asparaginase (Group A)
Number of subjects: 240
Study 31135888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 144
Study 31135888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 29570378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours before examination (Group 1, n = 1619)
Number of subjects: 3206
Study 29570378 — intervention group
Group type: COMPARATOR
Intervention: Light meal before examination (Group 2, n = 1587)
Number of subjects: 3206
Study 28118228 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific Web-based educational module
Number of subjects: 65
Study 28118228 — intervention group
Group type: COMPARATOR
Intervention: General patient safety Web-based educational module (Control)
Number of subjects: 65
Study 25125488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 64
Study 25125488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 64